Abstract
We analyse the costimulating role of CD40/CD40 ligand and B7/CD28 in inflammatory bowel diseases (IBD) as a potential target of antibody therapy. CD40, expressed by lamina propria B lymphocytes in gut mucosa, interacts with CD40 ligand on T cell. This interaction is implicated in the pathogenesis of IBD. In some animal models of colitis the anti-CD40L therapy demonstrated to be effective. Phase II trials on Crohn's disease are ongoing. B7.1 and B7.2, expressed by macrophages, interact with CD28, on T cell. B7.2 resulted implicated in ulcerative colitis, determining a Th2 pattern, whereas B7.1, a major Th1 stimulator, could be involved in Crohn's disease. In some animal models of colitis anti-B7.1, but not anti-B7.2, was effective. Anti B7 therapy was not yet tested in humans.
| Original language | English |
|---|---|
| Pages (from-to) | 65-70 |
| Number of pages | 6 |
| Journal | Acta Biomedica |
| Volume | 74 |
| Issue number | SUPPL. 2 |
| Publication status | Published - 2003 |
Fingerprint
Keywords
- CD40
- Crohn's disease
- Ulcerative colitis
ASJC Scopus subject areas
- Medicine(all)
Cite this
Role of CD40 and B7 costimulators in inflammatory bowel diseases. / Polese, Lino; Angriman, Imerio; Scarpa, Marco; Norberto, Lorenzo; Sturniolo, Giacomo Carlo; Cecchetto, Attilio; Ruffolo, Cesare; D'Amico, Davide Francesco.
In: Acta Biomedica, Vol. 74, No. SUPPL. 2, 2003, p. 65-70.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Role of CD40 and B7 costimulators in inflammatory bowel diseases
AU - Polese, Lino
AU - Angriman, Imerio
AU - Scarpa, Marco
AU - Norberto, Lorenzo
AU - Sturniolo, Giacomo Carlo
AU - Cecchetto, Attilio
AU - Ruffolo, Cesare
AU - D'Amico, Davide Francesco
PY - 2003
Y1 - 2003
N2 - We analyse the costimulating role of CD40/CD40 ligand and B7/CD28 in inflammatory bowel diseases (IBD) as a potential target of antibody therapy. CD40, expressed by lamina propria B lymphocytes in gut mucosa, interacts with CD40 ligand on T cell. This interaction is implicated in the pathogenesis of IBD. In some animal models of colitis the anti-CD40L therapy demonstrated to be effective. Phase II trials on Crohn's disease are ongoing. B7.1 and B7.2, expressed by macrophages, interact with CD28, on T cell. B7.2 resulted implicated in ulcerative colitis, determining a Th2 pattern, whereas B7.1, a major Th1 stimulator, could be involved in Crohn's disease. In some animal models of colitis anti-B7.1, but not anti-B7.2, was effective. Anti B7 therapy was not yet tested in humans.
AB - We analyse the costimulating role of CD40/CD40 ligand and B7/CD28 in inflammatory bowel diseases (IBD) as a potential target of antibody therapy. CD40, expressed by lamina propria B lymphocytes in gut mucosa, interacts with CD40 ligand on T cell. This interaction is implicated in the pathogenesis of IBD. In some animal models of colitis the anti-CD40L therapy demonstrated to be effective. Phase II trials on Crohn's disease are ongoing. B7.1 and B7.2, expressed by macrophages, interact with CD28, on T cell. B7.2 resulted implicated in ulcerative colitis, determining a Th2 pattern, whereas B7.1, a major Th1 stimulator, could be involved in Crohn's disease. In some animal models of colitis anti-B7.1, but not anti-B7.2, was effective. Anti B7 therapy was not yet tested in humans.
KW - CD40
KW - Crohn's disease
KW - Ulcerative colitis
UR - http://www.scopus.com/inward/record.url?scp=1542515288&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1542515288&partnerID=8YFLogxK
M3 - Article
VL - 74
SP - 65
EP - 70
JO - Acta Biomedica de l'Ateneo Parmense
JF - Acta Biomedica de l'Ateneo Parmense
SN - 0392-4203
IS - SUPPL. 2
ER -